Table 1

Correlation between clinicopathological features and CD8+ TILs change, FOXP3+ TILs change and the CD8/FOXP3 ratio

ParametersCD8+ TILs changeP valuesFOXP3+ TILs changeP valuesCD8/FOXP3 changeP values
Low
(n=73)
High
(n=56)
Low
(n=82)
High
(n=45)
Low
(n=59)
High
(n = 68)
Age at operation
  ≤56 years29 (39.7%)35 (62.5%)0.01337 (45.1%)26 (57.8%)0.19732 (54.2%)31 (45.6%)0.376
  >56 years44 (60.3%)21 (37.4%)45 (54.9%)19 (42.2%)27 (45.8%)37 (54.4%)
Tumour size
  ≤2 cm12 (16.4%)4 (7.1%)0.17711 (13.4%)5 (11.1%)0.7878 (13.6%)8 (11.8%)0.794
  >2 cm61 (83.6%)52 (92.9%)71 (86.6%)40 (88.9%)51 (86.4%)60 (88.2%)
Lymph node status
 Negative18 (24.7%)20 (35.7%)0.1824 (29.3%)13 (28.9%)0.96413 (22.0%)24 (35.3%)0.119
 Positive55 (75.3%)36 (64.3%)58 (70.7%)32 (71.1%)46 (78.0%)44 (64.7%)
Ki-67
  ≤14%36 (49.3%)26 (46.4%)0.85943 (52.4%)17 (37.8%)0.13828 (47.5%)32 (47.1%)0.964
  >14%37 (50.7%)30 (53.6%)39 (47.6%)28 (62.2%)31 (52.5%)36 (52.9%)
Intrinsic subtype
 TNBC22 (30.2%)16 (28.6%)0.94218 (21.9%)20 (44.4%)0.01421 (35.6%)17 (25.0%)0.426
 HER2BC9 (12.3%)8 (14.3%)10 (12.2%)7 (15.6%)7 (11.9%)10 (14.7%)
 HRBC42 (57.5%)32 (57.1%)54 (65.9%)18 (40.0%)31 (52.5%)41 (60.3%)
Pathological response
 Non-PR13 (17.8%)5 (8.9%)0.20210 (12.2%)8 (17.8%)0.43112 (20.3%)6 (8.8%)0.071
 PR60 (82.2%)51 (91.1%)72 (87.8%)37 (82.2%)47 (79.7%)62 (91.2%)
TILs (%) change
 Low53 (72.6%)14 (25.0%)<0.00150 (61.0%)15 (33.3%)0.00328 (47.5%)37 (54.4%)0.479
 High20 (27.4%)42 (75.0%)32 (39.0%)30 (66.7%)31 (52.5%)31 (45.6%)
CD8+TILs
 LowNot determinedNot determined51 (62.2%)22 (48.9%)0.18939 (66.1%)34 (50.0%)0.075
 High31 (37.8%)23 (51.1%)20 (33.9%)34 (50.0%)
FOXP3+ TILs
 Low51 (69.9%)31 (57.4%)0.189Not determinedNot determined21 (35.6%)61 (89.7%)
 High22 (30.1%)23 (42.6%)38 (64.4%)7 (10.3%)<0.001
CD8+/FOXP3+
 Low39 (53.4%)21 (37.5%)0.07321 (25.6%)38 (84.4%)<0.001Not determinedNot determined
 High34 (46.6%)35 (62.5%)61 (74.4%)7 (15.6%)
  • FOXP3, forkhead box protein; HER2BC, human epidermal growth factor receptor 2-enriched breast cancer; HRBC, hormone receptor-positive breast cancer; PR, partial response; TIL, tumour-infiltrating lymphocyte; TNBC, triple-negative breast cancer.